Refractory Anemia With Excess Blasts in Transformation Completed Phase 1 Trials for Tipifarnib (DB04960)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00005845Tipifarnib in Treating Patients With Myelodysplastic SyndromesTreatment